Mismatch between Bioluminescence Imaging (BLI) and MRI When Evaluating Glioblastoma Growth: Lessons from a Study Where BLI Suggested “Regression” while MRI Showed “Progression”

Simple Summary The GL261 murine preclinical model is one of the most commonly used models to study the impact of new GBM treatments. To assess tumor growth, the use of noninvasive imaging is needed. Bioluminescence imaging (BLI) is particularly popular because of its easy access compared to magnetic resonance imaging (MRI). In our study, by comparing in vivo tumor growth of wild-type and luciferase-expressing GL261 models, we observed a difference in the estimation of tumor growth by BLI and MRI in a specific model. The divergence in results was explained by the instability in luciferase expression after transduction. Our study showed that the use of multi-modality imaging prevents possible errors in tumor growth evaluation. Abstract Orthotopic glioblastoma xenografts are paramount for evaluating the effect of innovative anti-cancer treatments. In longitudinal studies, tumor growth (or regression) of glioblastoma can only be monitored by noninvasive imaging. For this purpose, bioluminescence imaging (BLI) has gained popularity because of its low cost and easy access. In the context of the development of new nanomedicines for treating glioblastoma, we were using luciferase-expressing GL261 cell lines. Incidentally, using BLI in a specific GL261 glioblastoma model with cells expressing both luciferase and the green fluorescent protein (GL261-luc-GFP), we observed an apparent spontaneous regression. By contrast, the magnetic resonance imaging (MRI) analysis revealed that the tumors were actually growing over time. For other models (GL261 expressing only luciferase and U87 expressing both luciferase and GFP), data from BLI and MRI correlated well. We found that the divergence in results coming from different imaging modalities was not due to the tumor localization nor the penetration depth of light but was rather linked to the instability in luciferase expression in the viral construct used for the GL261-luc-GFP model. In conclusion, the use of multi-modality imaging prevents possible errors in tumor growth evaluation, and checking the stability of luciferase expression is mandatory when using BLI as the sole imaging modality.

[1]  G. Vandermeulen,et al.  Combination of DNA Vaccine and Immune Checkpoint Blockades Improves the Immune Response in an Orthotopic Unresectable Glioblastoma Model , 2022, Pharmaceutics.

[2]  P. Dagur,et al.  Author Correction: GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models , 2022, Scientific Reports.

[3]  J. Sarkaria,et al.  Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain Tumor , 2021, Drug Metabolism and Disposition.

[4]  V. Préat,et al.  Nanomedicine: A Useful Tool against Glioma Stem Cells , 2020, Cancers.

[5]  K. Kataoka,et al.  Translational Nanomedicine Boosts Anti-PD1 Therapy to Eradicate Orthotopic PTEN-Negative Glioblastoma. , 2020, ACS nano.

[6]  Xianchun Zeng,et al.  An HIV-infected patient with coronavirus disease 2019 has a favourable prognosis: a case report. , 2020, Annals of palliative medicine.

[7]  L. Dubois,et al.  Use of a Luciferase-Expressing Orthotopic Rat Brain Tumor Model to Optimize a Targeted Irradiation Strategy for Efficacy Testing with Temozolomide , 2020, Cancers.

[8]  J. Wilmott,et al.  Temporal and spatial modulation of the tumor and systemic immune response in the murine Gl261 glioma model , 2020, PloS one.

[9]  D. Maric,et al.  GL261 luciferase-expressing cells elicit an anti-tumor immune response: an evaluation of murine glioma models , 2019, Scientific Reports.

[10]  Jong-Hee Chang,et al.  Effect of combined anti-PD-1 and temozolomide therapy in glioblastoma , 2018, Oncoimmunology.

[11]  J. Taube,et al.  Expression of LAG‐3 and efficacy of combination treatment with anti‐LAG‐3 and anti‐PD‐1 monoclonal antibodies in glioblastoma , 2018, International journal of cancer.

[12]  D. Covas,et al.  Image and motor behavior for monitoring tumor growth in C6 glioma model , 2018, PloS one.

[13]  Christopher M. Jackson,et al.  TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM , 2018, Oncoimmunology.

[14]  Xiaopei Huang,et al.  Generation of Luciferase-expressing Tumor Cell Lines. , 2018, Bio-protocol.

[15]  Y. Kanemura,et al.  Mouse Models of Glioblastoma , 2017 .

[16]  Binsheng Zhao,et al.  Aggressive resection at the infiltrative margins of glioblastoma facilitated by intraoperative fluorescein guidance. , 2017, Journal of neurosurgery.

[17]  Christopher M. Jackson,et al.  Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM , 2016, Science Translational Medicine.

[18]  C. Drake,et al.  Agonist anti-GITR monoclonal antibody and stereotactic radiation induce immune-mediated survival advantage in murine intracranial glioma , 2015, Journal of Immunotherapy for Cancer.

[19]  D. M. Mofford,et al.  Luciferins behave like drugs. , 2015, ACS chemical neuroscience.

[20]  O. Feron,et al.  Dynamic contrast‐enhanced MRI in mouse tumors at 11.7 T: comparison of three contrast agents with different molecular weights to assess the early effects of combretastatin A4 , 2014, NMR in biomedicine.

[21]  T. Dresselaers,et al.  In vivo and ex vivo assessment of the blood brain barrier integrity in different glioblastoma animal models , 2014, Journal of Neuro-Oncology.

[22]  C. James,et al.  Immunocompetent murine models for the study of glioblastoma immunotherapy , 2014, Journal of Translational Medicine.

[23]  Katherine W Ferrara,et al.  Multimodal imaging enables early detection and characterization of changes in tumor permeability of brain metastases. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[24]  Bih-Rong Wei,et al.  Bioluminescent imaging of drug efflux at the blood–brain barrier mediated by the transporter ABCG2 , 2013, Proceedings of the National Academy of Sciences.

[25]  X. Golay,et al.  A Comparison of Imaging Techniques to Monitor Tumor Growth and Cancer Progression in Living Animals , 2011, International journal of molecular imaging.

[26]  M. Preul,et al.  Intracranial implantation with subsequent 3D in vivo bioluminescent imaging of murine gliomas. , 2011, Journal of visualized experiments : JoVE.

[27]  W. Hickey,et al.  Current review of in vivo GBM rodent models: emphasis on the CNS-1 tumour model , 2011, ASN neuro.

[28]  Cynthia Ng,et al.  Luciferase expression and bioluminescence does not affect tumor cell growth in vitro or in vivo , 2010, Molecular Cancer.

[29]  R. Mirimanoff,et al.  Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.

[30]  A. Kaufmann,et al.  Glioblastoma , 2006, Neurology.

[31]  M. Dewhirst,et al.  Use of in vivo bioluminescence imaging to predict hepatic tumor burden in mice. , 2004, The Journal of surgical research.

[32]  Z. Paroo,et al.  Validating bioluminescence imaging as a high-throughput, quantitative modality for assessing tumor burden. , 2004, Molecular imaging.

[33]  B. Rice,et al.  In vivo imaging of light-emitting probes. , 2001, Journal of biomedical optics.

[34]  Johnf . Thompson,et al.  Modulation of firefly luciferase stability and impact on studies of gene regulation. , 1991, Gene.

[35]  D. Placantonakis,et al.  Bioluminescent In Vivo Imaging of Orthotopic Glioblastoma Xenografts in Mice. , 2018, Methods in molecular biology.

[36]  Christian E Badr,et al.  Bioluminescence imaging: basics and practical limitations. , 2014, Methods in molecular biology.

[37]  Jisook Lee,et al.  In vivo measurement of glioma-induced vascular permeability. , 2011, Methods in molecular biology.

[38]  V. Baekelandt,et al.  In vivo bioluminescence imaging in an experimental mouse model for dendritic cell based immunotherapy against malignant glioma , 2008, Journal of Neuro-Oncology.

[39]  T. Blackwell,et al.  Bioluminescence imaging. , 2005, Proceedings of the American Thoracic Society.

[40]  J. Koutcher,et al.  MRI of mouse models for gliomas shows similarities to humans and can be used to identify mice for preclinical trials. , 2002, Neoplasia.

[41]  L. Deangelis,et al.  Brain Tumors , 2019, Imaging Gliomas After Treatment.

[42]  Daniel E. Hall,et al.  Rapid and quantitative assessment of cancer treatment response using in vivo bioluminescence imaging. , 2000, Neoplasia.